CELG

Celgene Corporation Press Releases

$118.57
*  
2.14
1.77%
Get CELG Alerts
*Delayed - data as of Mar. 6, 2015 12:55 ET  -  Find a broker to begin trading CELG now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    CELG Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By

























Celgene Corporation to Webcast at Upcoming Investor Conferences
1/27/2015 8:30:00 AM - Business Wire
▼-3.52 % Price Change since this news event. The Volume Ratio is 0.96.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Celgene Receives Positive CHMP Opinion for ABRAXANE® for First-Line Treatment of Patients with Non-Small Cell Lung Cancer
1/23/2015 7:19:00 AM - Business Wire
▼-4.14 % Price Change since this news event. The Volume Ratio is 0.8.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Oral OTEZLA® (apremilast) Approved by the European Commission for the Treatment of both Patients with Psoriasis and Psoriatic Arthritis
1/16/2015 9:10:00 AM - Business Wire
▼-0.32 % Price Change since this news event. The Volume Ratio is 0.72.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Celgene Corporation Announces 2015 and Long-Term Financial Outlook and Preliminary 2014 Results
1/12/2015 10:58:00 AM - Business Wire
▲2.21 % Price Change since this news event. The Volume Ratio is 2.13.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Celgene Corporation to Present at the 33rd Annual J.P. Morgan Healthcare Conference
1/6/2015 8:30:00 AM - Business Wire
▲5.16 % Price Change since this news event. The Volume Ratio is 1.56.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Celgene Receives Positive CHMP Opinion to Extend REVLIMID® (Lenalidomide) for Continuous Use in Patients with Newly Diagnosed Multiple Myeloma and Ineligible for Transplant
12/19/2014 8:10:00 AM - Business Wire
▲1.65 % Price Change since this news event. The Volume Ratio is 1.97.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Combination of ISTODAX® (romidepsin) and Standard CHOP Demonstrates a Complete Response in 51% of Patients with Peripheral T-Cell Lymphoma
12/9/2014 2:00:00 PM - Business Wire
▲0.05 % Price Change since this news event. The Volume Ratio is 1.45.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Results from Phase IIIb Study of POMALYST®/IMNOVID® (pomalidomide) Plus Low-Dose dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma Presented at ASH
12/8/2014 9:05:00 PM - Business Wire
▼-0.02 % Price Change since this news event. The Volume Ratio is 1.18.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day






Additional Analyses of High-Risk Patients from Phase III Study (AML-001) OF Vidaza® (Azacitidine for Injection) in Acute Myeloid Leukemia Presented at ASH
12/8/2014 8:05:00 PM - Business Wire
▼-0.02 % Price Change since this news event. The Volume Ratio is 1.18.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day